2 enrolling by invitation. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Enrolling by invitation 2 |
| Phase 1 | 1 | Enrolling by invitation 1 |
Follow Nevi and Melanomas: new trials by email Literature Review of Nevi and Melanomas trials Research Report on Nevi and Melanomas
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Learn About the Long-Term Health of Adult Participants From a Previous Study of a New Melanoma Treatment Fianlimab+cemiplimab - Melanoma | Phase 2 | Enrolling by invitation | Regeneron Pharmaceuticals | 48 | 2025-04-14 | 2026-07-13 |
| Melphalan Chemoreduction for Ocular Melanoma Melphalan Injection, Plaque brachytherapy - Uveal Melanoma | Phase 1 / Phase 2 | Enrolling by invitation | Hospital das Clínicas de Ribeirão Preto | 10 | 2021-05-01 | 2025-09-15 |
Melanoma (2) · Uveal Melanoma (1)
Neoplasms (2) · Neoplasms by Histologic Type (2) · Neoplasms by Site (2) · Neoplasms, Germ Cell and Embryonal (2) · Neoplasms, Nerve Tissue (2) · Neuroectodermal Tumors (2) · Neuroendocrine Tumors (2) · Skin Diseases (2) · Skin Neoplasms (2) · Skin and Connective Tissue Diseases (2) · Eye Diseases (1) · Eye Neoplasms (1) · Uveal Diseases (1) · Uveal Neoplasms (1)
Brachytherapy (1) · Melphalan (1) · Radiotherapy (1) · Ruthenium-106 (1) · cemiplimab (1)
Hospital das Clínicas de Ribeirão Preto (1) · Regeneron Pharmaceuticals (1)
Brazil (1) · Ireland (1) · United States (1)